Results for tag: "Dupilumab"

Dupilumab is a monoclonal antibody used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It works by blocking the action of a protein called interleukin-4 (IL-4) and interleukin-13 (IL-13), which are involved in inflammation. Dupilumab is approved for use in adults and adolescents aged 12 years and older with moderate-to-severe asthma, and for adults with moderate-to-severe COPD. It is administered as an injection under the skin. Dupilumab is a relatively new drug, and is the first biologic therapy approved for the treatment of asthma and COPD. It has been shown to reduce symptoms and improve lung function in patients with these conditions. It is also being studied for use in other respiratory diseases, such as eosinophilic asthma and bronchiolitis obliterans syndrome. Some companies in the Dupilumab market include Regeneron Pharmaceuticals, Sanofi, and AstraZeneca. Show Less Read more